Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States

References

• Anand, A., and A. Hosanagar. 2022. The addictive potential and challenges with use of the “herbal supplement” Kratom: A case report and literature review. Pain Medicine (Malden, Mass) 23 (1):4–9. doi:10.1093/pm/pnab126.
   PubMed Web of Science ®Google Scholar
• Bestha, D. 2018. Kratom and the opioid crisis. Innovations in Clinical Neuroscience 15 (5–6):11.
   PubMedGoogle Scholar
• Black, J. C., A. Forber, S. G. Severtson, K. Rockhill, K. P. May, E. Amioka, J. Schwarz, J. Iwanicki, and R. C. Dart. 2021. Drug product dispensing and estimates of use in a general population survey as a signal detection problem. Pharmacoepidemiology and Drug Safety 30 (8):1132–39. doi:10.1002/pds.5260.
   PubMed Web of Science ®Google Scholar
• Black, J. C., K. Rockhill, A. Forber, E. Amioka, K. P. May, C. M. Haynes, N. Dasgupta, and R. C. Dart. 2019. An online survey for pharmacoepidemiological investigation (survey of non-medical use of prescription drugs program): Validation study. Journal of Medical Internet Research 21 (10):e15830. doi:10.2196/15830.
   PubMed Web of Science ®Google Scholar
• Brown, P. N., J. A. Lund, and S. J. Murch. 2017. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna Korth: Implications for products sold as kratom. Journal of Ethnopharmacology 202:302–25. doi:10.1016/j.jep.2017.03.020.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality (2021). Racial/Ethnic differences in substance use, substance use disorders, and substance use treatment utilization among people aged 12 or older (2015-2019) (Publication No. PEP21-07-01-001)) Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data.
   Google Scholar
• Giroir, B. P. (2018). Letter from the assistant secretary of health to the administrator of the drug enforcement administration. Accessed on October 10, 2022. https://images.go02.informamarkets.com/Web/Informa02/%7b548e6d56-2ea4-4da4-9404-0348b56e9a88%7d_dhillon-8.16.2018-response-letter-from-ash-radm-giroir.pdf.
   Google Scholar
• Griffin, B. A., M. S. Schuler, E. A. Stuart, S. Patrick, E. McNeer, R. Smart, D. Powell, B. D. Stein, T. L. Schell, and R. L. Pacula. 2021. Moving beyond the classic difference-in-differences model: A simulation study comparing statistical methods for estimating effectiveness of state-level policies. BMC Medical Research Methodology 21 (1):279. doi:10.1186/s12874-021-01471-y.
   PubMed Web of Science ®Google Scholar
• Griffin, O. H., 3rd, J. A. Daniels, and E. A. Gardner. 2016. Do you get what you paid for? An examination of products advertised as Kratom. Journal of Psychoactive Drugs 48 (5):330–35. doi:10.1080/02791072.2016.1229876.
   PubMed Web of Science ®Google Scholar
• Grundmann, O. 2017. Patterns of Kratom use and health impact in the US-Results from an online survey. Drug and Alcohol Dependence 176:63–70. doi:10.1016/j.drugalcdep.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Grundmann, O., C. A. Veltri, D. Morcos, D. Knightes III, K. E. Smith, D. Singh, O. Corazza, E. Cinosi, G. Martinotti, Z. Walsh, et al. 2022. Exploring the self-reported motivations of Kratom (Mitragyna speciosa Korth.) use: A cross-sectional investigation. The American Journal of Drug and Alcohol Abuse 48 (4):433–44. doi:10.1080/00952990.2022.2041026.
   PubMed Web of Science ®Google Scholar
• Halpenny, G. M. 2017. Mitragyna speciosa: Balancing potential medical benefits and abuse. ACS Medicinal Chemistry Letters 8 (9):897–99. doi:10.1021/acsmedchemlett.7b00298.
   PubMed Web of Science ®Google Scholar
• Hao, Z., and B. W. Cowan. 2020. The cross-border spillover effects of recreational marijuana legalization. Economic Inquiry 58 (2):642–66. doi:10.1111/ecin.12764.
   Web of Science ®Google Scholar
• Henningfield, J. E., D. W. Wang, and M. A. Huestis. 2022. Kratom abuse potential 2021: An updated eight factor analysis. Frontiers in Pharmacology 12:775073. doi:10.3389/fphar.2021.775073.
   PubMed Web of Science ®Google Scholar
• Palamar, J. J. 2021. Past-year kratom use in the U.S.: Estimates from a nationally representative sample. American Journal of Preventive Medicine 61 (2):240–45. doi:10.1016/j.amepre.2021.02.004.
   PubMed Web of Science ®Google Scholar
• Palamar, J. J. 2022. Kratom use is underestimated, but prevalence still appears to be low. American Journal of Preventive Medicine 62 (1):133–34. doi:10.1016/j.amepre.2021.07.021.
   PubMed Web of Science ®Google Scholar
• Prozialeck, W. C., B. A. Avery, E. W. Boyer, O. Grundmann, J. E. Henningfield, A. C. Kruegel, L. R. McMahon, C. R. McCurdy, M. T. Swogger, C. A. Veltri, et al. 2019. Kratom policy: The challenge of balancing therapeutic potential with public safety. The International Journal on Drug Policy 70:70–77. doi:10.1016/j.drugpo.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Rothberg, R. L., and K. Stith. 2018. Fentanyl: A whole new world? Journal of Law, Medicine & Ethics 46 (2):314–24. doi:10.1177/1073110518782937.
   PubMed Web of Science ®Google Scholar
• Schimmel, J., E. Amioka, K. Rockhill, C. M. Haynes, J. C. Black, R. C. Dart, and J. L. Iwanicki. 2021. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: A cross-sectional study. Addiction (Abingdon, England) 116 (1):176–81. doi:10.1111/add.15082.
   PubMed Web of Science ®Google Scholar
• Smith, K. E., K. E. Dunn, J. M. Rogers, O. Grundmann, C. R. McCurdy, A. Garcia-Romeu, D. Schriefer, M. T. Swogger, and D. H. Epstein. 2022. Kratom use as more than a “self-treatment”. The American Journal of Drug and Alcohol Abuse Advance online publication. 48(6):684–94. doi:10.1080/00952990.2022.2083967.
   PubMed Web of Science ®Google Scholar
• Smith, K. E., and T. Lawson. 2017. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence 180:340–48. doi:10.1016/j.drugalcdep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Striley, C. W., C. C. Hoeflich, A. T. Viegas, L. A. Berkowitz, E. G. Matthews, L. P. Akin, C. Iheanyi-Okeahialam, U. Mansoor, and C. R. McCurdy. 2022. Health Effects associated with kratom (Mitragyna speciosa) and polysubstance use: A narrative review. Substance Abuse: Research and Treatment 16:11782218221095873. doi:10.1177/11782218221095873.
   Web of Science ®Google Scholar
• Swogger, M. T., E. Hart, F. Erowid, E. Erowid, N. Trabold, K. Yee, K. A. Parkhurst, B. M. Priddy, and Z. Walsh. 2015. Experiences of kratom users: A qualitative analysis. Journal of Psychoactive Drugs 47 (5):360–67. doi:10.1080/02791072.2015.1096434.
   PubMed Web of Science ®Google Scholar
• Weiss, S. T., and J. Brent. 2023. A cautionary tale of herbal supplements: What we have learned from Kratom. Current Addiction Reports 10 (1):1–8. doi:10.1007/s40429-023-00465-8.
   Google Scholar
• Williams, R. S., and D. Nikitin. 2020. The internet market for Kratom, an opioid alternative and variably legal recreational drug. The International Journal on Drug Policy 78:102715. doi:10.1016/j.drugpo.2020.102715.
   PubMed Web of Science ®Google Scholar